What is Corbus Pharmaceuticals Holdings Financial Strength?
Corbus Pharmaceuticals Holdings has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Corbus Pharmaceuticals Holdings did not have earnings to cover the interest expense.
As of today, Corbus Pharmaceuticals Holdings's Altman Z-Score is 0.00.
Competitive Comparison of Corbus Pharmaceuticals Holdings's Financial Strength
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Financial Strength falls into.
Corbus Pharmaceuticals Holdings Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Corbus Pharmaceuticals Holdings's Interest Expense for the
months ended in Mar. 2024 was $-0.18 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-9.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.86 Mil.
Corbus Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is
| Corbus Pharmaceuticals Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Corbus Pharmaceuticals Holdings's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Corbus Pharmaceuticals Holdings has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description
Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Executives
| Yong Ben |
director |
500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Anne Altmeyer |
director |
500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Yuval Cohen |
director, officer: Chief Executive Officer |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Craig Stuart Millian |
officer: Chief Commercial Officer |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Sean F. Moran |
officer: Chief Financial Officer |
10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
| Rachael Louise Brake |
officer: Chief Scientific Officer |
21 MANCHESTER PLACE, NATICK MA 01760 |
| George Golumbeski |
director |
C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Peter Salzmann |
director |
320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
| Barbara White |
officer: Chief Medical Officer |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Robert Paul Discordia |
officer: Chief Operating Officer |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Rachelle Suzanne Jacques |
director |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| David P Hochman |
director |
15 WESTON HILL RD., RIVERSIDE CT 06878 |
| John Kenneth Jenkins |
director |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
| Paris Panayiotopoulos |
director |
ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Alan F Holmer |
director |
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your